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The following Investment Committee paper focuses on a proposal for a leveraged buyout on Elekta AB, a key player in the global radiotherapy market which sells in more 
than 120 countries. In fact, this paper develops a set of value creation strategies (with an emphasis on the Buy & Build strategy) through a detailed analysis of the 
radiotherapy market and of the competitive advantages of the company. Subsequently, a capital structure is suggested by assessing past buyout transactions in the 
healthcare sector and by leveraging the bank case. Finally, the exit returns are estimated complying with industry threshold and a range of exit strategies are analyzed. 
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Disclaimer: This Work Project was prepared by a group of students from Nova School of Business and Economics as the Master’s Thesis for the Master in Finance 
Program. We, hereby, pledge on our honor that the work presented is ours and that none dishonest method was used in its execution. Furthermore, we declare that this 
Work Project is intended to be used for academic purposes only. Therefore, we restrain ourselves from taking any responsibility from the wrong usage of the content 
presented, namely any investment or legal action taken grounded on it. 
This Work Project was developed using publicly available data and information provided by the company (i.e., annual reports, investor relations, presentations, etc.). The
sources of the information are disclosed when appropriated.
This Work Project is divided into three complementary parts. For an integral analysis of the Work Project please see the remaining two parts named “Power of Proton
Solutions in Radiotherapy Market” and “APAC’s Influence in the Future of Radiotherapy Market”.
This work used infrastructure and resources funded by Fundação para a Ciência e a Tecnologia (UID/ECO/00124/2013, UID/ECO/00124/2019) and Social Sciences




Elekta AB is a Swedish manufacturer of radiotherapy
medical equipment. Its products and aftermarket
services are sold to both public and private sector;
Its product portfolio consists of linear accelerators,
magnetic resonance imaging linear accelerators
(MR-Linacs), brachytherapy, oncology informatic
solutions (OIS) and neurosolutions;
Elekta provides a range of quality services that
include maintenance, updates, training, among
others;
With an emphasis in customization, Elekta has been
one of the main leaders in the radiotherapy market.
COMPANY PROFILE
Elekta seems to be an exciting investment opportunity yielding an investors’ return of 3.14x
DEAL RATIONALE
VALUE CREATION & EXIT AND RETURNS
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INDUSTRY PROFILE
Elekta is distinguished by its efficiency and has reached
a leading position in emerging markets
Strong Cash-Flow Generation
Brand Prestige and Market Leadership
Free Cash Flow generated by the company is robust
and has been stable over the past few years
Strategic value-adding acquisitions allowed Elekta to
become a key player in radiotherapy market
Acquisition history
Sizeable and Growing Market
Optimistic industry growth prospects, since cancer




Radiotherapy is one of the main types of cancer
treatment. With cancer incidence expected to
increase until 2040, significant investments have
been made in the oncology market;
Accordingly, the radiotherapy market is expected to
increase at a CAGR of 7.3% until 2029, from a $6.6B
value in 2019;
This growth will be mainly driven by innovations in the
sector (namely MR-Linacs and OIS), and the
increasing demand for radiotherapy, as 60% of
cancer patients are expected to need it.
4
o It is expected that the increase in revenues and the
improvement of EBITDA margin, will create SEK
50,629M of value;
o With the deleveraging effect, the investment will
generate SEK 57,500M of value.
o The fund will generate a combined return of 3.45x in
five years (IRR of 28.07%);
o Institutional investors and managers will have
returns of 3.14x and 136.1x respectively.
Financials 2020 2021F 2022F 2023F 2024F 2025F
Organic Sales 14,601 14,722 19,506 22,571 24,214 26,390
% growth - 1% 32% 16% 7% 9%
Org EBITDA 2,921 3,088 4,170 4,814 5,280 5,886
Inorg Sales N/A 0 3,134 4,839 5,584 6,018
% growth - - - 54% 15% 8%
HCG 0 0 3,134 3,302 3,887 4,144
IBA 0 0 0 1,537 1,697 1,874
Inorg EBITDA N/A 0 275 634 784 892
EBITDA 2,921 3,088 4,445 5,449 6,065 6,778
% mg 20% 21% 20% 20% 20% 21%





COMPANY OVERVIEW | PROFILE
o Founded in 1972, its headquarters are located
in Stockholm, Sweden. It has been listed in the
OMX Nordic Exchange since 1994 and currently
employs more than 4,000 people;
o ELEKTA is one of the key players in the global
radiotherapy market, providing radiotherapy
equipment in order to treat different types of
cancer and brain disorders;
o The company sells both to the public and
private sector (hospitals, private clinics) in more
than 120 countries;
o Elekta has a wide range of suppliers – 80%
of sourced products/services come from
approximately 450 suppliers. In some specific
products (MR Linac–Image) there is only one
supplier, which might increase the shortage risk;
o Its position in the value chain is as a medical
equipment manufacturer and software
provider, that has been distinguished by its
innovation and efficiency. It is also known by
customizing their products for each specific
client. The main activities of the production units
are assembly, testing and quality assurance;
COMPANY PROFILE RANGE OF PRODUCTS
Elekta is one of the key players in the global radiotherapy market (radiation therapy & radiosurgery)
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Offers leading solutions in both
radiotherapy treatment and
oncology informatics systems.














PIONEERS IN PRECISION RADIATION MEDICINE
Rank
% Margin
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Sources: Elekta’s Annual Report and Website
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COMPANY OVERVIEW | PRODUCT MIX
Elekta’s diversified product portfolio enables this company to thrive in the radiotherapy market
201720132008 2018
Sources: Elekta’s Annual Report and Website; Investor Presentation 2018
2003
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COMPANY OVERVIEW | GROWTH DRIVERS AND GEOGRAPHICAL BREAKDOWN
Securing improved financial performance as well as operational excellence 
PROFITABILITY DRIVERS
ELEKTA’S ACQUISITION HISTORY
o Elekta’s market share 40%
o Net Sales 31% 
o Solutions 72%
o Services 28%
o Elekta’s market share 43%
o Net Sales 38%
o Solutions 64%
o Services 36%
o Elekta’s market share 21%
o Net Sales 31%
o Solutions 44%
o Services 56%
North and South America EMEA APAC
o Expanding Product Portfolio i.e Brachy Solutions and MRI Linacs
gives access to more potential customers;
o Market need for cost-efficient and digitalized cancer care can be
exploit by Elekta, since it is a key player which provides high-quality
solutions and services;
o Its Precision Radiation Medicine - easier to use, improve patient
experience, increase workflow - can lead to strong customer’s
relationship, increasing clients’ long-term brand loyalty;
o Gross Margin and SG&A margin improvement by increasing the
efficiency in internal processes. Elekta wants to replicate its Harmony
Solution COGS reduction in the other innovative products already
provided, in order to improve its gross margin. By sharing services and
digitalization (remote assistance; remote conferences) it aims to reduce
its SG&A costs (COVID also helped in reducing travel expenses);
NeuromagPhilips Radiation 
Therapy Division 











2014/1520111972 20062005 20081997 2003 2018/20
$20M $75M €365M >SEK 178M
Linear Accelerators;        Oncology Informatics;        Stereotactic Radiosurgery;        Brachytherapy;      MR–Linear Accelerators  
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Market defined by innovative procedures
that will continue to play a major role in
cancer treatment.
EMEA
MARKET OVERVIEW | A BROADER PICTURE OF RADIOTHERAPY
RADIOTHERAPY MARKET AROUND THE WORLD
o The market is steadily growing in Western Europe due to increasing capacity and renovation of
equipment. Private Sector’s role plays an important role, but national programs are the main
responsible for funding cancer treatments, care and research;
o In Eastern Europe there is still a lack of infrastructure, but national services have been developing;
o In Middle East and Africa there is still a considerable lack of resources. However, increasing
awareness of the problems of cancer, the increasing demand in the Middle East and the
emergence of Turkey as a fast-growing market, make MEA a long-term attractive region.
AMERICAS
o North America market is characterized by a prominence of private providers that have
consolidated their position over the years, creating a competitive environment. 60% of North
American patients are treated with radiotherapy and there is increasing demand to renew existent
equipment;
o In South America there is a mix of public and private sector, existing inadequate accessibility to
public services;
o Nevertheless, the emergence of healthcare groups which are investing in radiotherapy clinics and
a need for modernization will drive the market forward in the next years.
APAC
o China is the most important market in the Asia-Pacific region, with the government incentivizing
the expansion of radiotherapy, both in capacity and renewing equipment;
o Japan has one of the biggest growth potential, as 70% of cancer patients do not receive
radiotherapy. Hong-Kong, Australia, Singapore and South Korea are also mature markets with
adequate levels of investment in radiotherapy;
o India also expects a long-term growth in radiotherapy demand. Currently, radiotherapy is more
prominent in the private-sector, but it in the long-term the public sector will increase its investment.




CAGR of 7.3%     
until 2029
Up to 60% of cancer patients need
radiotherapy solutions. However, around
half of them are unable to access it. The
different states of development between
regions are key determinants to access rates
to radiotherapy solutions.
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Sources: Elekta’s Annual Report and Website; Grandviewresearch
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MARKET OVERVIEW | COMPETITIVE LANDSCAPE
Pursuit of the best cost-effective solutions that
could offset structural differences between
countries and regions.
Constant search for innovation (e.g., current
pandemic enhanced the importance of remote
monitoring and maintenance).
Acquisitions and partnerships play a key
role on differentiation and market share
gains.
Elekta’s main competitor is Varian but emergent markets dominance could offset discrepancies 
MARKET COMPETITIVE DYNAMICS
5 FORCES OF PORTER
Attracting and retaining the most qualified
employees
Companies must ensure that their products
are reimbursed as much as possible.
Protection of patients to maintain value














1 Competition in the industry       ►
2 Potential of new entrants           ►
3 Power of suppliers                     ►
4 Power of customers                  ►
5 Threat of substitute products   ►
➢ Competition based on R&D investment, cost-
efficiency and after-market services;
➢ Only Varian has an overlap with Elekta’s product
portfolio but there are significant number of
companies which address specific segments;
➢ High capital needs, strong and consolidated
companies within the market, existence of patents
and regulation complexity could strongly harm the
entrance of new competitors;
Low   Moderate   High
➢ In general, there is a wide range of suppliers which
cover raw materials and principal components needs,
implying lower bargaining power;
➢ However, some specific materials only provided by
few suppliers (Elekta’s MRI) increase their power;
➢ Prevalence of long-term contracts allied with high
customization pattern enhances the importance of
negotiation. Usually, the manufacturers have to adjust
the given solution in order to fulfill the customer
needs;
➢ High investment in R&D could imply short product
life-cycles, however long-term contracts secure
customer loyalty, thus diminishing this threat.
Papers, peer reviews and clinical data are
important to attract customers
Supremacy of service revenues as
companies try to maximize clients’ loyalty
and recurrent revenues by ensuring
maintenance and support services
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o Elekta is a key player of cancer treatment
equipment distinguished by its efficiency
o The company has reached leading position in
China and strong market share positions in
Americas (21%), EMEA (43%) and Asia
Pacific (40%)
Strong Cash-Flow Generation
Brand Prestige and Market Leadership
o Free Cash Flow generated by the company has
been stable over the past few years
o Moreover, Cash Flow from Operating Activities
has ranged in the last three years between SEK
1000M and SEK 2400M
INVESTMENT THESIS| DEAL RATIONALE & VALUE CREATION STRATEGIES
o Elekta’s history is highly influenced by strategic
acquisitions that have allowed Elekta to widen
its portfolio, differentiate its products from the















Sizeable and Growing Market
o Optimistic radiotherapy industry growth
prospects over the next 5 years, since cancer
incidence is increasing all over the world, with
most markets currently underserved
o Governments are willing to allocate more money
in cancer care, as well as private sector
Accelerating Market Growth 
o MR-Linear Accelerators are set to continue to revolutionize radiotherapy. Therefore,
this market is expected to grow 20% a year. Elekta AB, being the major player in this
segment is well positioned to capitalize on this growth. Moreover, Elekta’s investment
in R&D will be key to consolidate its market position, by offering customized products
that are a key competitive advantage
o MEA and APAC markets are currently underserved, and the trend does not favour
them, since both will have the higher growths of cancer incidence (%) until 2040. This
creates an opportunity for ELEKTA to expand and consolidate its leadership
position in these regions: by taking advantage of its current brand reputation and by
leveraging its geographic presence through the acquisition of an APAC distributor
o Elekta will try to consolidate its position in the remaining markets. The South American
market is currently underserved, but its political and economical unstable climate are

























o Leverage competitive position by acquiring consolidated companies that broaden
Elekta’s product portfolio and are also in line the company’s high standard of precision
and efficiency. In line with internationalization, the acquisition of strategic distributors
will play a key role in Elekta’s short-term strategy. The company might also acquire





o Enhance transformation program pillars and exploit further improvement opportunities.
Continue investment in R&D, reduce COGS and SG&A by leveraging on digitalization
initiatives (remote services, cloud computing) and consolidate lower-cost
manufacturing solutions (replicate Harmony’s cost structure)
Software Distributors Proton Solutions
Nova School of Business and Economics | Private Equity Challenge: ELEKTA AB | January 2021 
Sources: Interview with Investor Relations
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Elekta has a variety of compelling value creation strategies that can enhance its key player position 
Founded in 2003, Micropos develops medical
devices for high precision 4D therapy. The
company manufactures an accessory for radiation
therapy machines to increase the precision and
efficiency of prostate cancer treatment.
Elekta would try to expand the 4D functionalities to
other types of cancers and leverage
hypofractionation (more precision, treatment in




































Notes: 1) Not included in Investment Case
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Elekta’s Buy & Build targets will contribute to strengthen Elekta’s position
Sources: HCG, IBA and Micropos’ websites, Reuters
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IBA (Ion Beam Applications) was founded in 1986,
from the Catholic University of Louvain-la-Neuve’s
Cyclotron Research Center (Belgium). Although its
primary emphasis started to be medical imaging, the
company moved its focus to proton therapy.
By acquiring one of the key players in the proton
therapy segment, Elekta will be well positioned to
capitalize on the proton therapy market’s growth
and consolidate its position as a global leader in the
radiotherapy segment.
Founded in 1989, Healthcare Global Enterprises is
one of the largest cancer care provider in India,
having a network of over 20 cancer centers spread
across India. Currently employs almost 6,000
people.
The acquisition of Healthcare Global Enterprises is
a major opportunity for Elekta’s expansion in
India and Africa, as it is a key distributor in the
market, since it already operates in both locations,
enhancing Elekta’s internationalization strategy.
Sales growth (proton solutions contributing with 23%);
Expand Elekta’s portfolio to cover all segments
radiotherapy market;
Increase worldwide proton market share.
Sales growth (across all Elekta’s product
portfolio);
Strengthen competitive position in APAC and
in Africa regions (more predominance in APAC).
Implement this feature in Elekta´s different
solutions portfolio in a medium/long term
perspective – apply to different cancers.






































The financials compromise the success of this
acquisition thus it was excluded from our forecast.
Free Cash Flow (M SEK) 2018 2019 2020 2021F 2022F 2023F 2024F 2025F CAGR 
20-25F
EBITDA 2,520 2,616 2,921 3,088 4,445 5,449 6,065 6,778 18.3%
Adjustments:
Change in Net Working Capital 1,665 -265 -1,212 218 -542 -920 -117 -216
Tax -203 -197 -184 -203 -409 -514 -574 -659
Maintenance Capex -816 -659 -762 -1,759 -2,238 -2,764 -3,116 -3,488
%revenues -7.1% -4.9% -5.2% -11.9% -9.9% -10.1% -10.5% -10.8%
Acquisition Capex - - - - -3371 -1943 - -
Cash flow before financing 
(Free cash flow - FCF)
3,166 1,495 763 1,345 (2,115) (693) 2,258 2,415 25.9%
%Growth (53%) (49%) 76% (257%) 67% 426% 7%
FCF (excl. acquisition 
capex)
3,166 1,495 763 1,3445 1,256 1,250 2,258 2,415 
• FCF excluding acquisition capex strengthens from
2020 to 2025 – growing at a CAGR of 25.9% and
reaching SEK 2,415M at exit. In 2022F and 2023F it
decreased, mainly attributable to the acquisitions of
IBA and HCG and variations of change in NWC;
o Elekta’s EBITDA will increase from SEK 2,921M in
2020 to SEK 6,778M in 2025, corresponding to a
CAGR of 18.3%. Its main drivers were HCG and
IBA acquisitions and organic growth;
BUSINESS PLAN | FINANCIALS FORECAST – FREE CASH FLOW
Robust cash flow generation driven by a solid EBITDA growth 
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FCF vs FCF excl Acquisition CAPEX FCF Breakdown
6
• Change in NWC will be positive in 2021F mainly
because of Covid-19 effects (increased average
payable/collection period). From this point onwards
it will come back to 2019 and 2020 values (being
less variable than it used to be);
2
• Tax includes tax shields from D&A and deductible
interest expenses assuming a 24% income tax.
3
• The acquisition of IBA and HCG in 2022F and
2023F respectively, represents a considerable cash















2018 2019 2020 2021F 2022F 2023F 2024F 2025F
Cash flow before financing (Free cash flow - FCF)










 EBITDA Change in NWC CAPEX FCF
• Maintenance Capex will range between 10-12% of
revenues based on forecasted Total Fixed Assets
and acquisitions of IBA and HCG.
4
4
o The Gross Profit can be divided
into revenues growth and gross
margin improvement;
o Revenues will increase over the
investment period from 14,601M to
32,408M due to the implementation of
the value creation strategies, leading
to an impact of 3,562 in EBITDA;
o Gross margin will improve from
42.6% (2020) to 44.6% (2025) due to
economies of scale and the
acquisition of HCG, leading to an
impact of 633M in EBITDA.
BUSINESS PLAN | FINANCIALS FORECAST – EBITDA BRIDGE
EBITDA will double until 2025 due to an increase of revenues and improvement of margins
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o The Covid-19 pandemic enhanced a
continuation of operational
improvements (digitalization, reduction
of travelling) that will drive the
reduction of these costs’ weights on
revenues;
o The integration of HCG and IBA will
somewhat offset these improvements,
as both companies have lower margins,
compared to ELEKTA, leading to a
negative impact of EBITDA margin of
338M.
EBITDA GROWTH DRIVERS
Gross Profit EBITDA Margin
EBITDA GROWTH BRIDGE
Organic Growth
o Elekta will continue to develop
and enhance all its radiotherapy
solutions, however, MR-Linacs
and OIS will have the most
significant growths, as their
respective markets will increase
significantly over the next years;
o As a result, organic growth will
add SEK 1,272M to Elekta’s
EBITDA.
o As the market leader of proton
therapy, IBA is expected to
contribute with an additional SEK
1,542M to Elekta’s EBITDA over
four years, helping Elekta consolidate
its position as a leader in
radiotherapy.
o The acquisition of HCG will help
Elekta boost its revenues in all its
radiotherapy solutions in APAC and
some African regions. Consequently, it
is projected that Elekta’s EBITDA is
increased by SEK 1,044M.
IBA & HCG 
MSEK MSEK
BUSINESS PLAN | MANAGEMENT PACKAGE
MANAGEMENT PACKAGE
Management incentive package contains sweet equity, a bonus payment and a PSU’S plan
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PSU'S PLAN 2021E 2022E 2023E 2024E 2025E
% of sweet equity 0.50% 0.50% 0.75% 0.75% 1%
If Gross Profit and EBITDA are met at 100%
Gustaf Salford 0.27% 0.27% 0.40% 0.40% 0.54%
Johan Adebäck 0.11% 0.11% 0.16% 0.16% 0.21%
Paul Bergström 0.06% 0.06% 0.10% 0.10% 0.13%
Jonas Bolander 0.06% 0.06% 0.10% 0.10% 0.13%
If Gross Profit and EBITDA are met at 85%
Gustaf Salford 0.16% 0.16% 0.24% 0.24% 0.32%
Johan Adebäck 0.06% 0.06% 0.10% 0.10% 0.13%
Paul Bergström 0.04% 0.04% 0.06% 0.06% 0.08%
Jonas Bolander 0.04% 0.04% 0.06% 0.06% 0.08%
VESTING RULES 2021E 2022E 2023E 2024E 2025E
Final Sweet Equity Stake 15.0%
% Sweet Equity Vested 
per year
10% 25% 40% 80% 100%
Vested Equity Stake 1.50% 3.75% 6.00% 12.00% 15.00%
Management proceeds 74 658 1,638 4,175 6,681
Gustaf Salford 43 383 954 2431 3890
Johan Adebäck 14 125 311 793 1269
Paul Bergström 8 75 187 476 761
Jonas Bolander 8 75 187 476 761
PSU’S PLAN
A long-term incentive based on performance-vested shares contingent
upon achieving EBITDA and Gross Profit annual levels. The promised number
of shares are in line with the additional % of sweet equity defined on the
table to the right and will be split across management considering their entry
equity - if MM is lower than 2.50x they will not be rewarded.
3
Total Remuneration Bonus Payment
Gustaf Salford 15027 2216                                                 
Johan Adebäck 4901 875                                                
Paul Bergström 2940 525                                              
Jonas Bolander 2940 525                                                
TOTAL 25809 4141
In 2021, an immediate bonus payment will be paid to management, equal to
25% of their fixed annual salary amount. This payment will leverage
management’s motivation in the current pandemic context.
BONUS PAYMENT 2
25%
PARTICIPATION IN SWEET EQUITY
Managers will be required to invest twice its total annual salary in exchange
for a 15% equity stake which will be vested accordingly with the table.
The four members of the management team will have different equity stakes
(accordingly with their salaries and positions):
1
• Gustaf Salford will invest SEK 30.05M and receive 58% of sweet equity;
• Johan Adebäck will invest SEK 9.80M and receive 19% of sweet equity;
• Paul Bergström and Jonas Bolander will invest SEK 5.88M each and 
receive 11% of sweet equity.
1
3










EXIT & RETURNS | ENTRY MULTIPLE
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ENTERPRISE VALUE (M SEK)
DCF – EXIT MULTIPLE METHOD
o This DCF is based on a EV/EBITDA multiple
of 13.13x used to compute the terminal value.
o To discount the FCF, it was used a WACC of
6.64%, which is decomposed on Appendix X
o This valuation was not included in the final




o Considering the same list of 6 comparables, a
valuation through one-year forward
EV/EBITDA multiples was computed, arriving




DCF – GORDON’S GROWTH
o The DCF using Gordon’s growth model was
performed with a terminal growth rate (TGR)
of 2.5% (in line with market prospects – e.g.
increase of cancer incidence).
o It was not included in the final EV as it is
mainly explained by the terminal value




o Considering a qualitative and quantitative
analysis (i.e. similar EBITDA margin and capital
structure) it was possible to list 6 comparables.
o Using one-year forward P/E multiples, the
minimum value was 22.71x while the




o This valuation methodology was computed
based on past transactions in the cancer
care industry.
o It was possible to verify that there is recurring
discrepancies in the multiples’ value, ranging




o A 10-year cycle adjustment was made for
both multiples used in the comparables
analysis to eliminate one-time events.
o In general, there has been a multiples’






Considering different methodologies, an EV/EBITDA of 13.13x and an EV of SEK 38,339M was arrived
Sources and Uses of Funds:
Sources of Funds
▪ They are distributed between Debt (5x EBITDA – 14,605M) and Equity (8.8x EBITDA – 25,651 M);
▪ Total Debt is allocated among two tranches (A and B) - Term A amortized senior Debt of 2,921M – 1x
EBITDA and Term B bullet payment senior Debt of 11,684M – 4x EBITDA.
▪ Equity is divided in FRI (25,307M – 8.7x EBITDA) and Ordinary Equity (344M – 0.1x EBITDA).
Uses of Funds
▪ Total Uses of funds corresponds to SEK 40,256M, distributed into EV (38,339M – 95%) and Fees
(1,917M – 5%);
Scenarios – Capital Structure:
▪ Scenario 1 was chosen in favor of number 2 and 3, as it constitutes a more conservative approach
(better Cash Cover, Interest Coverage and Debt/EBITDA), without compromising the minimum
threshold of the investor’s returns. In comparison with scenario 9, scenario 1 was chosen because it
presents better returns for investors.
EXIT & RETURNS | CAPITAL STRUCTURE
Sources of funds will be composed of 63.7% equity and 36.3% debt
























SOURCES & USES OF FUNDS1



















SCENARIOS – CAPITAL STRUCTURE
FINAL RATIONALE
Notes: 1) Including cash overfunding – used on acquisitions
SCENARIOS 1 2 3 9
Leverage 5.0x 6.0x 5.5x 4.5x
IRR 24.00% 25.74% 24.83% 23.23%
MM 2.93x 3.14x 3.03x 2.84x
Cash Cover
SCENARIOS Term A Term B Term C 2021 2022 2023 2024 2025
1 1.0x 4.0x 0.0x 1.4x 1.5x 1.5x 2.1x 2.3x
2 1.0x 5.0x 0.0x 1.2x 1.4x 1.4x 1.9x 2.1x
3 1.0x 4.5x 0.0x 1.3x 1.4x 1.5x 2.0x 2.2x
9 1.0x 3.5x 0.0x 1.4x 1.6x 1.6x 2.2x 2.4x
EXIT & RETURNS| EXIT WATERFALL & CREDIT STATISTICS
The fund’s investors will have a return of 3.14x, corresponding to an IRR of 25.7% 
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EXIT WATERFALL BRIDGE
MSEK
The presented credit statistics imply that all covenants will be respected
(computed via conservative bank case) under the predicted investment case
scenario. Specifically, Cash Cover (excluding acquisitions) and Interest Cover will
start with 1.4x and 7.2x multiple, respectively, and will increase over the investment
period as the firm is more capable of paying debt obligations. Debt/EBITDA will start
at 4.6x in 2021 and will decrease to 1.8x at the year of exit due to Term Loan A
amortization and EBITDA increase. The cash amount was excluded from this analysis
since its value is abnormal due to overfunding.
Summary Credit Stats 2021F 2022F 2023F 2024F 2025F
Cash Cover 1.4x 1.5x 1.5x 2.1x 2.3x
Cash Covenant 1.0x 1.0x 1.0x 1.0x 1.0x
Interest Cover 7.2x 10.3x 11.9x 13.5x 16.5x
Interest Covenant 6.4x 7.5x 8.7x 9.4x 10.8x
Debt / EBITDA 4.6x 3.1x 2.5x 2.1x 1.8x
Leverage Covenant 5.1x 4.5x 3.8x 3.4x 3.0x
CREDIT STATISTICS
In 2025, management receives proceeds of SEK 6,681M, corresponding
to a MM of 129.4x and an IRR of 164.5% (PSU Plan included);
Institutional investors receive, in the exit year (2025), SEK 75,037M,
which translates in a return of 2.93x (MM) and an IRR of 24.0%
Returns 2021F 2022F 2023F 2024F 2025F
Management Exit 
Proceeds
74 658 1,638 4,175 6,681
Management Entry Equity 52 52 52 52 52




32,491 45,842 56,384 65,139 75,037
Institutional Investor 
Equity
25,599 25,599 25,599 25,599 25,599
Institutional Returns 1.27x 1.79x 2.20x 2.54x 2.93x
IRR 24.0%
In 2025, a combined value (EV + Cash) of SEK 94,132M will be distributed into debt
repayments, investors and managers. At exit, debt value will be SEK 12,414M, since it
is still left to repay SEK 730M of Term Loan A (amortized over 6 years) and the total of
Term Loan B (because it is amortized only at year seven).
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STRATEGIC SALE IPOSECONDARY SALE
EXIT OPTIONS & DUE DILIGENCE | EXIT OPTIONS & TARGET BUYERS
A strategic sale implies that another major player







More expensive process – High
transaction costs (e.g. underwriter fees are
the largest)
Access to capital markets, increasing
significantly the number of potential buyers
comparing with the other exit solutions.
Because such acquisition would bring
benefits for the acquirer (i.e., synergies), it
is likely that the transaction value would
include a premium, increasing the returns
for the fund;
The feasibility of this option is highly
dependent on finding a suitable target
acquirer. In this particular case, because
Elekta AB is one of the biggest players in
radiotherapy, a target buyer would
probably have to come from another
sector closely related to radiotherapy;
Moreover, a strategic sale is usually slower
than a secondary sale. Furthermore, strategic
sales are losing popularity in this sector,
having decreased from 40% to 33% in 2018.
In the last years, PE exit through IPO’s in
healthcare industry were mainly linked to
biopharma smaller-stage companies.
It has become more frequent following the PE
sector increasing trend. The Exit Value of
Healthcare PE industry increased in 2019 to
$40.8B, compared with $31.6B in 2018,
moreover, secondary sale transactions
represented 53% in 2019;
ELEKTA is an attractive buyout target –
healthy CF and room to become the market
leader of radiotherapy industry (high growth
potential);
Industry’s strong returns allied and
resilience at any stage of the economic
cycle. In addition, this strategy is faster than
the alternatives;
Increasing interest from strategic buyers
lead to higher entry valuations which are
unattractive to potential PE buyouts;
Dependent on market conditions and
specific timings that could harm fund’s exit
and returns.
Sources: Bain & Company Report “Healthcare Exits”
Typically, the fund is not able to sell all 
its equity position, thus increasing the 
overall risk of the exit (i.e. subject to post-
IPO market reaction and loss of control)
INDIVIDUAL 
SECTION
COMPANY OVERVIEW | PRODUCT MIX & TRANSFORMATION PROGRAM
SERVICES
Data based allied with AI enable proactive contact and maintenance in the service and support offering
o Elekta has a portfolio of services that support customers from installation throughout
the lifetime of their Elekta product (ELEKTA CARE). The services range from
installation, maintenance, training and technology update options.
o Elekta’s services organization consists of more than 650 field engineers and 165
support specialists, backing up field engineers, who provide remote assistance to
Elekta’s global network support centers in different time zones and in local languages;
o Through Elekta Care Community portal, customers can access personalized
content and share knowledge through a global peer-to-peer network;
o Elekta IntelliMax connects more than 18,000 Elekta products. It continuously
monitors incoming data and diagnose patterns that predict failure of components
before they occur, leading to considerable time savings (average 8 hours of clinical











Solutions vs Services 
solutions services
2016                        2017                       2018                       2019                        2020
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▪ Optimize staff clinical abilities;
▪ Provide full control - lifecycle 
costs.
SILVER




▪ Maximize operational excellence;
▪ Safeguard clinical availability;
▪ Minimize unexpected lifecycle 
costs.
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2016 2017 2018 2019 2020
Services (M SEK)
Main Outputs Main Goals
NWC : <5% of Net Sales
Implement produce-to-
order
EBITDA mg:  20% 2018 
Cost Savings: SEK 
700M 2018
Optimize its internal processes
Change its support remote services
Benefit from acquisitions’ synergies
Improve profitability and cashflow
Increase efficiency in marketing & sales
Reduce administrative spending.
o In 2016, Elekta’s changed its strategic direction towards long-term
profitable growth. The company focused on high growth areas, such as
services and software and shortened its lead times from production to
installation (Produce-to-Order process - is aligned with the high-level of
customization products provided by Elekta) enhancing improvements in
inventory management;
COMPANY OVERVIEW | MANAGEMENT TEAM
CEO & CFO 
• Elekta’s CEO since June
2020, after the departure
of Dr. Richard Hausmann.
Previously held the
position of CFO and
executive vice-president.
• He has worked for Elekta
since 2009 and has a
Master’s in Business
Administration (BA).







• He has worked for Elekta
since 2004, having held
various senior finance
management roles, and
has a Bachelor in BA.
Elekta’s management team is divided into products and geographical areas
Global Executive Vice-Presidents (EVP)
• Paul Bergström joined
Elekta as an Executive
Vice President and
Head of Global Services
at Elekta in November
of 2017.
• He has a Master in
Electrical Engineering
from Royal Institute of
Technology, Stockholm.
• Jonas Bolander currently
holds the position of
General Counsel and
EVP. He is responsible
for many governance
aspects of the company
such as audits and
internal controls.
• He has joined Elekta in
2001 and has a Master
of Laws.
ANALYSIS
The members of the management
team have been employed by
Elekta for an average of 12.25
years.
All of them, with the exception of
Paul Bergstrom, have held
positions in Elekta, highly related
with their current ones.
Their education is in accordance
with their current position. Only
Paul Bergström’s master might not
be fully aligned with his position.
Verdict: Having all these in account, we
consider the management team to be
the right one to take Elekta forward.
Even though, both CEO and CFO have
only been in their current offices for a few
months, their knowledge of the company
are an assurance that they are fit.
Other considerations: The rest of Elekta’s
management is divided into products and
geographical areas, which allows for a
more efficient management and better
decision-making
Gustaf Salford Johan Adebäck Paul Bergström Jonas Bolander
BOARD OF DIRECTORS
8 Board Members
Compensation&Sustainability Committee Audit Committee
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Strategic Fit: Strategic Fit: Strategic Fit: Strategic Fit:
Overall Management 
Team Strategic Fit:
Low   Moderate   High
MSEK 2016 2017 2018 2019 2020
Solutions 7,052 6,210 7,054 8,392 8,845
Services 4,169 4,494 4,519 5,163 5,756
Net sales 11,221 10,704 11,573 13,555 14,601
Growth net sales (%) - -4.61% 8.12% 17.13% 7.72%
Cost of products sold -6,540 -6,227 -6,465 -7,829 -8,379
Gross income 4,681 4,477 5,108 5,726 6,222
Gross margin 41.7% 41.8% 44.1% 42.2% 42.6%
Selling expenses -1,211 -1,026 -1,071 -1,164 -1,290
Administrative expenses -943 -856 -887 -974 -843
R&D expenses -707 -624 -671 -892 -871
Exchange rate differences -165 -201 41 -80 -297
Adjusted EBITDA 1,655 1,770 2,520 2,662 2,943
EBITDA margin 14.7% 16.5% 21.8% 19.5% 20.1% In 2018/19, the gross margin decreased due to a change of
product mix (Elekta Unity was introduced) and because of price
pressure in consolidated markets for LINAC products;
SEK M 2016 2017 2018 2019 2020
Region North and South America
% Solutions 51% 50% 48% 49% 44%
% Services 49% 50% 52% 51% 56%
Europe, Middle East and Africa
% Solutions 63% 58% 65% 65% 64%
% Services 37% 42% 35% 35% 36%
Asia Pacific
% Solutions 76% 68% 70% 73% 72%
% Services 24% 32% 30% 27% 28%
In 2018 there was a significant increase in the EBITDA margin. There was a strong order
growth and net sales development during this year, while the operating expenses remained
almost the same (Transformation Program started to have effect – improving internal processes),
which led to a significant increase of EBITDA margin;





Despite solutions being 60% (net sales) and services 40%, sales
behave differently regionally: Services’ are higher in developed
economies - Americas, while Solutions’ prevail in least developed
economies, like EMEA and APAC markets;
1
The net sales were quite volatile. In 2017, the transformation
program had a negative impact, (e.g. new produce-to-order
process). In the following years, it had a steep increase in revenues
mainly through a growing market share in APAC, EMEA. In 2020,
Covid-19 deaccelerated the company revenues;
Selling expenses remained the same over the last 5 years (while
Administrative decreased (Transformation Program -
digitalization) – SG&A decreased from 21% to 17% of revenues
R&D expenses increased (9-11% of revenues) since the company
continues to innovate and digitalize its portfolio
2
4
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Other operating income and 
expenses - - - 23 111
Notes: 1) Not included in Adjusted EBITDA
MSEK 2016 2017 2018 2019 2020
Accounts receivable 3,301 3,726 3,402 3,455 3,379
Average Collection Period 107 127 107 93 84
Inventories 1,135 936 2,560 2,634 2,748
Average Holding Period 63 55 145 123 120
Accrued income 2,126 1,640 1,160 1,401 1,526
Other current receivables 741 802 1,068 1,059 1,208
Working Capital Assets 7,303 7,104 8,190 8,549 8,861
Accounts payable 1,122 1,000 1,132 1,427 1,025
Average Payable Period 63 59 64 67 45
Other 5,912 6,792 9,411 9,210 8,712
Working Capital Liabilities 7,034 7,792 10,543 10,637 9,737
Net Working Capital 269 -688 -2,353 -2,088 -876
%net sales 2.4% -6.4% -20.3% -15.4% -6.0%
Cash and cash equivalents 2,273 3,383 4,458 4,073 6,407
Long-term interest-bearing liabilities 3,065 5,272 4,369 3,558 7,101
Short-term interest-bearing liabilities 1,885 - 975 1,000 1,000
Total Debt 4,950 5,272 5,344 4,558 8,101
Net Debt 2,677 1,889 886 485 1,694
Tangible fixed assets 803 795 895 957 968
Intangible assets 8,210 8,704 9,175 9,301 9,469
Other 2,349 2,547 2,261 2,079 7,033
Capital Employed 11,362 12,046 12,331 12,337 17,470
ROCE 3.72% 4.96% 14.96% 13.75% 9.48%
Net debt/EBITDA 1.62 1.07 0.35 0.18 0.58
COMPANY OVERVIEW | HISTORICAL FINANCIALS (2/3)
According to 2015 transformation program, Net
Working Capital is set to be less than 5% of net
sales - this value has been negative since 2016/17.
From 2018/19 to 2019/20, total debt increased due
to a rise in long-term interest-bearing liabilities.
This is mainly due to two bank loans finalized in April
2020 – one of SEK 300 million (two years) and one
of GBP 90 million (seven years) and an increase of
SEK 1,250 million in lease liabilities because of the
adoption of IFRS 16.
Capital Employed has historically been around
SEK 12,000 million. However, in 2019/2020 it
increased to SEK 17,470 million. This is explained
by the recognition of right-of-use assets since May
2019 and the increase in cash and cash equivalents
which both led to a rise in total assets value.
Net debt/EBITDA ratio has been decreasing,
from 1.62 in 2015/16 to 0.18 in 2018/19, having
increased again in 2019/20. This is mainly explained
by a decrease in Net Debt In 2019/20, as the
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1
Notes: 1) Elekta started to adopt IFRS 15, which caused a significant positive adjustment of Inventories and WC Liabilities
1
Net working capital has been increasing in the last
years, which is mainly explained by the decrease on
operating liabilities (mainly on Accounts payables and
advances from customers). It is important to notice that
fluctuations in working capital are common, since it
depends on the progress of projects and the timing of
certain events in relation to terms in the contract (i.e.
payments from customers might not coincide with the
recognition of revenue resulting in either assets (accrued
income) or liabilities (advances from customers)).
1
Continuous investments have been quite stable, since
investments in intangibles are related with ongoing R&D
programs and R&D expenses don’t vary much over time
(10% of revenues as benchmark). Also, investments in
other assets (e.g. equipment and machinery) have been
consistently around SEK 200M per year.
2
COMPANY OVERVIEW | HISTORICAL FINANCIALS (3/3)
Efficiency, R&D capitalization and borrowings lead the cash flow changes
COMMENTS
Cash flow from financing activities are mainly explained
by the YoY changes on borrowings (i.e. difference
between new borrowings and debt payments). In fact,
during 2019, there was a significant rise in long-term
interest-bearing liabilities linked with two bank loans that
were contracted, which explains the sharp increase on
cash flow in this year.
3
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MSEK 2016 2017 2018 2019 2020
EBITDA 1,655 1,770 2,520 2,616 2,921
Income taxes paid -268 -268 -250 -269 -261
Operating cash flow 709 766 2,358 2,256 2,527
Change in working capital 461 1,051 46 -636 -1,512
Cash flow from operating activities 1,170 1,817 2,404 1,620 1,015
Continuous investments -774 -774 -816 -659 -762
Investments intangible assets -596 -633 -642 -458 -566
Investments other assets -192 -141 -212 -201 -196
Sale of fixed assets 14 0 38 0 0
Cash flow after investments 384 1,025 1,447 945 -284
∆ Borrowings -1,107 169 15 -938 3,516
Cash flow from financing activities -1,303 -55 -367 -1,473 2,623
Cash flow for the year -919 970 1,080 -528 2,339




When one looks at the effort that has been put into fighting cancer, there are no
doubts about the seriousness of this disease. Over the past years, there has
been a great investment in early diagnosis, treatments and innovative
therapies, palliative cares and medical follow-up.
Despite a great advance in understanding and fighting cancer, there is still a long
road ahead in all this variants. According to WHO report “Cancer Control: A Global
Snapshot in 2015”, most European countries reported a participation rate for
cervical cancer screening inferior to 70% in the target of group, with many of them
having a rate inferior to 50%. This figures are even more dramatic in under-
developed countries, where are very few efforts put into early diagnosis.
Given this facts, there is little to no surprise that the markets for these variants will
continue to increase significantly. For example, the cancer therapeutics market
was valued at $133 million in 2017 and is expected to reach $200 million in
2022. It is unquestionable that the players in these markets will fight to keep
revolutionizing the market. Nevertheless, it is up to each country to set policies that
ensure that the fight against cancer will have a positive outcome.
Considered by many one of the most prominent diseases of the 21st
century, cancer relates to a type of disease that causes some body’s cells to
start dividing without any control, eventually causing the invasion of nearby
tissues.
Cancer can happen in almost any tissue of the human body and can affect
anyone due to a variety of reasons that include environmental factors, genetics,
human behavior (i.e. smoking, diet, etc.), viruses, etc.
In fact, according to the World Health Organization (WHO), in 2018, 9.6 millions
of deaths were caused by cancer (approximately one in six deaths), making
cancer the second biggest cause of death. Furthermore, the same
organization estimated that there were around 18 million cancer cases diagnosed
in 2018 alone. It is expected that this number reaches 29 million in 2040.
However, as new trends emerge in our society, it is believed that the real figures
can go up to 37 million. There is no doubt that cancer is and will continue to be
a main challenge for society to face in the upcoming years.
CANCER AND ITS EFFECT ECONOMICS BEHIND CANCER
Cancer is one of the biggest challenges of the 21st century, affecting millions of people every year
MARKET OVERVIEW | CANCER IN THE 21ST CENTURY
50,000 people are diagnosed with cancer every day
26,300 people die of  cancer every day
Nova School of Business and Economics | Private Equity Challenge: ELEKTA AB | January 2021 21
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The healthcare market is heavily regulated. Such regulation is easily understood, as there must exist mechanisms to ensure that citizens have access to only
appropriate healthcare services and products. Therefore, it is up to governments to create such regulators in the way they operate to both patients and healthcare
providers’ benefit. Moreover, countries’ governments must also invest on healthcare infrastructure (i.e. hospitals, research centers) and services (i.e.
reimbursements, insurances, etc.). If countries do not have a valuable investment policy on healthcare, it is almost impossible for healthcare providers to operate.
o According to the Organization for Economic Co-Operation and Development (OECD), healthcare spending in percentage of GDP has been
growing, and it is estimated that this will remain the case in the future. In 2018, OECD countries spent on average 8.8% of their GDP in
healthcare.
o But as healthcare systems around the world are becoming more and more under pressure, a global trend to align market incentives with efficient
and quality therapies has emerged, even if individual healthcare systems among countries is fundamentally different.
DEVELOPED COUNTRIES UNDERDEVELOPED COUNTRIES
Developed countries are characterized by high
investments in cancer diagnosis and treatments. For
instance, according to “Cancer Control: A Global Snapshot in
2015”, almost 80% of high-income countries have specific
programs to early diagnose breast cancer (70% in colon
cancer).
Moreover, these countries have been spending
significantly in hospitals, education and research,
meaning that there is a considerable symbiose between
governments and companies in the healthcare sector that
can use existent resources to operate. This symbiose
translates to higher cancer diagnosis and survival rates.
Underdeveloped countries lack infrastructure to support
healthcare investment. Consequently, there is few
investment in these markets by healthcare private
providers. This means that most of the population in low-
income countries have inadequate access to these
services. According to the same report, less than 30% low-
income countries report to have cancer treatment services
generally available.
Although it is highly expected that the investment in health
will increase, it is not likely that some low-income
countries will constitute a good investment opportunity
for private companies in the upcoming years.
MARKET OVERVIEW | HEALTH SYSTEMS AND GOVERNMENTS
Government’s policies and actions are key determinants to successfully treat cancer
8.8%
of GDP
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MARKET OVERVIEW | SOLUTIONS, PLAYERS AND MARKET TRENDS OF RADIOTHERAPY
LINEAR 
ACCELERATORS







Linear Accelerators the  
are most common 
used solution in 
radiotherapy.
As demand for 
radiotherapy is 
increasing, linear 
accelerators role will 
remain crucial as they 
are used to treat a wide 
range of cancers.
Linear Accelerators are 
the most valuable 
solution in the 
radiotherapy market. It 
is estimated to grow at 
a CAGR of over 7% 
until 2025. 
As progress is made to 
increase survival rates 
in cancer, innovative 
features such as real 
time monitoring 
during treatment will 
play a major role in the 
future of radiotherapy 
and other oncology 
treatment therapies. 
MRI oriented 
radiotherapy solutions is 
expected to play a major 
role in radiotherapy in 
the future. In 2018 it 
was valued at $220 
million, but it can 




Every cancer case is 
unique. Therefore, to 
successfully cure 
cancers is mandatory 
that health-care 
professionals have 
access to the necessary 
data to make the best 
decisions. The digital 
innovation that make 
not only all this 
possible, but also 
remote consultations 
will drive the market 
forward. 
In 2017, it was valued at 
$2,622  million, and it 
will reach $4,569 
million by 2025.
The strive for 
precision to reduce the 
damage of healthy 
tissue and to allow 
giving doses in smaller 
fractions has been 
playing a major role in 
radiotherapy and will 
continue to do so. This 
trend aligned with the 
trend of reducing 
invasiveness will drive 
the market forward.
The brachytherapy 
market was valued at 
$348.8 million in 2017 
and is projected to 
grow at a CAGR of 
4.6% until 2025.
The increasing 
understanding of the 
brain, the strive for 
higher precision and 
the search for cost-
efficient solutions (that 
allow more patients to 
be treated) are key 
market trends that 
explain the popularity 
of this solution.
The market for 
stereotactic radiosurgery  
is projected to grow at 
a CAGR of 6.1% until 
2025, with Asia-Pacific 
expecting the highest 
growth.
As new therapies have 
been developed to 
increase success in 
cancer treatments, 
protons solutions are set 
to play a major role due 
to an increase of 
cancer cases near 
sensitive organs (i.e.
nerves, skull, etc.), 
and the strive for 
reducing 
invasiveness.
The  market for proton 
solutions was valued at 
$825 million in 2020 is 
projected to grow at a 
CAGR of 14.9% until 
2030.



















Nova School of Business and Economics | Private Equity Challenge: ELEKTA AB | January 2021 
Sources: Fact.MR; Grandviewresearch; Mordorintelligence; Alliedmarketresearch; Venturekick
23
Nova School of Business and Economics | Private Equity Challenge: ELEKTA AB | January 2021 
This work project was, undoubtfully, an amazing and challenging experience
24
MASTER THESIS
PRIVATE EQUITY – PERSONAL PERCEPTION 
INDIVIDUAL REFLECTION | 41196
The Master’s Thesis was an interesting and challenging project, specially because of the difficult times (i.e., Covid-19) we live in. During this Work Project, I was able to
develop my knowledge in many core finance areas related with Private Equity, such as Financial Reporting (by analyzing annual reports and other financial statements);
Corporate Valuation (by performing different methods of valuation of a few companies); and Financial Modeling (by developing Excel models). Not only this, but I was
also able to strengthen my Private Equity knowledge, as we had to make value creation strategies (for our investment thesis), an LBO model and a management
investment package.
Furthermore, during this Master’s Thesis I had the opportunity to strengthen my soft skills, such as time management (as we had strict deadlines); communication skills
(by talking with workers of Elekta AB and industry experts); and problem-solving (through all the thesis).
Last, but not the least, this experience was enriched by the opportunity of doing it with two supportive and hard-working friends.
Private Equity is a core and essential part of the financial world, moving many companies forward by creating value through the application of many strategies that are
inherent to Private Equity firms. As a Master in Finance student who had taken the Private Equity trimestral course, I was eager to learn more about this important
segment.
It is with great pride that I can say that I am now more aware of the profound research that Private Equity firms must do to in order to identify potential targets to acquire,
both in terms of market research (such as growth drivers of the market, market trends, historic and projected growth, size, value chain, etc.) and company (competitive
advantages, profitability drivers, historic M&A strategies, management profile and suitability, etc.) and to identify opportunities to grow and add value, increasing the
returns of the fund.
Moreover, and specifically about the healthcare sector, I learned that Private Equity firms are investing more and more in this sector, as there is a global trend to strength
healthcare services and it is a sector heavily influenced by mergers and acquisitions, with many opportunities to consolidation (by acquiring smaller players) and
expansion (to emergent markets). Additionally, this also means that there are a lot of possible and adequate exit strategies, such as selling to a big company or to sell to
another Private Equity firm.
It was also interesting to understand how the pandemic of Covid-19 is and will (continue to) influence Private Equity, not only in terms of new investments and possible
exits in the short-term, but also in the long-term in the sense that Private Equity firms will move even more towards investing in non-cyclical business segments that are
not largely dependent on the overall growth of the global economy.
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Websites lead the path on finding information about ELEKTA / Radiotherapy Market
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